Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis
Table 3
Comparison of liver disease and outcomes among HCV patients.
aPRR/aMR
LCL
UCL
p-value
Liver cirrhosis
0.81
0.72
0.91
0.0004
Liver cancer
0.79
0.55
1.13
0.2013
Complications of cirrhosis
Ascites
0.62
0.50
0.76
<0.0001
Variceal bleeding
1.03
0.75
1.40
0.8658
Hepatorenal syndrome
0.78
0.42
1.45
0.436
Hepatic encephalopathy
0.68
0.38
1.20
0.1824
Portal hypertension
0.71
0.56
0.91
0.0065
Jaundice
0.64
0.34
1.20
0.1633
Baveno4
0.97
0.93
1.02
0.2167
Health care utilization
Inpatient mortality
0.84
0.60
1.17
0.298
Length of stay
0.99
0.93
1.05
0.6319
Total hospital cost
0.87
0.80
0.95
0.0012
Unfavourable discharge
0.85
0.77
0.95
0.0025
aPRR: adjusted prevalence rate ratio; aMR: adjusted mean ratio (LOS and total hospital cost). LCL and UCL: lower and upper confidence limit; : effects are after adjusting for cirrhosis.
